Amgen Reports Second Quarter 2021 Financial Results
The Pharma Data
AUGUST 3, 2021
We expect that recovery in the dermatology segment will continue to progress over the coming quarters. For the remainder of the year, we expect continued growth from Kyprolis use in combination with CD38 antibodies. Looking forward, we are preparing for the anticipated approval of the mild-to-moderate psoriasis indication in the U.S.,
Let's personalize your content